No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GMED240517P55000
- 0.15
- -4.05-96.43%
15min DelayClose May 8 15:59 ET
0.20High0.12Low
0.20Open4.20Pre Close22 Volume97 Open Interest55.00Strike Price275.00Turnover51.83%IV-11.15%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type-0.0670Delta0.0263Gamma411.53Leverage Ratio-0.0351Theta-0.0009Rho-27.59Eff Leverage0.0124Vega
Intraday
- 5D
- 1D
News
Express News | Globus Medical Inc : Barclays Raises Target Price to $85 From $83
Barclays Reaffirms Their Buy Rating on Globus Medical (GMED)
Globus Medical's Strong Quarter Tempered by NuVasive Merger Complexities: A Hold Rating
Top Gap Ups and Downs on Wednesday: UBER, BUD, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 227.32K in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 3,500 shares of its common stock on May 8, with a total market value of approximately $227.32K. Sou
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 1.3 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 20,000 shares of its common stock on May 8, with a total market value of approximately $1.3 million.
Comments
The company's CEO, Dan Scavilla, expressed confidence in Pfeil's ability to drive operational efficiency and deliver profitable growth, especially in light of the ongoing integration following their merger with NuVasive.
Press Release: Globus Medical Promotes Keith Pfeil to Chief Operating Officer and Chief Financial OfficerGlobus Medical's superior earnings outlook is contributing to its high P/E, which shareholders are currently comfortable with, expecting not to face a threat to future earnings. The confidence in the future earnings performance supports the current share price.
Globus Medical's persisting issues impact its valuation and a drop in EPS may spark shareholder worry. The long-term share performance is lackluster, unsettling even potential contrarian investors seeking a turnaround.
Read more